Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz’s Saynor Leads IGBA’s CEO Advisory Committee

Chief Executive Chairs Panel As Lupin CEO Vinita Gupta Is Named Vice-Chair

Executive Summary

Sandoz chief executive Richard Saynor has been named as chair of the IGBA’s CEO advisory committee, which was first convened earlier this year. At the same time, Lupin CEO Vinita Gupta has been made vice-chair.

You may also be interested in...



IGBA CEO Panel Sets Out Priorities For Supply-Chain Resilience

After a meeting in Vienna, the IGBA’s CEO advisory committee has outlined four key areas in which action is needed to bolster supply-chain security and ensure pandemic prevention, preparedness and response.

Wave Of New Leaders Could Reshape Generics Industry

With a number of top generics and biosimilars firms announcing new leaders over the past few months, the industry could be in for some strategic shifts as new faces take the helm at established off-patent players.

Finger On The Pulse: The State Of Biopharma Leadership

In Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel